IPS examines need for new drugs to treat neglected tropical diseases

Inter Press Service News Agency examines the shortcomings of treatments for neglected tropical diseases - which, according to the Drugs for Neglected Diseases Initiative (DNDi), account "for 12 percent of the global disease burden," and 1.3 percent of the new drugs developed between 1975 to 2004.

"The diseases in question account for the deaths of 500,000 people annually, mostly in sub-Saharan Africa, but drug development is biased towards the prospect of high profits, which diseases of the poor like sleeping sickness and visceral leishmaniaisis are unable to offer," IPS writes.

"The pharmaceutical industry does not see neglected diseases as a market, because these diseases affect poor people with few resources. Therefore they are not a big market," Marcel Tanner, chairman of the DNDi board of directors, told IPS during a meeting last month in Nairobi to discuss new ways to tackle NTDs.

"Existing therapies [for neglected tropical diseases] are often toxic, prohibitively costly and difficult to administer," and overwhelm health personnel, IPS writes. The article also addresses efforts to prevent the spread of neglected tropical diseases, through the distribution of insecticide-treated nets and improved sanitation (Mulama, 7/6).


Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
World Antimicrobial Awareness Week 2022: What is the burden of antimicrobial resistance?